FDA ANDA · ANDA217870
CABOZANTINIB S-MALATE
Sponsor: CIPLA
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
ANDA217870
TYPE
ANDA
ORIGINAL APPROVAL
2026-10-16
LATEST ACTION
2026-10-16
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
CABOZANTINIB S-MALATEPrescription
CABOZANTINIB S-MALATE EQ 60MG BASE · TABLET · ORAL
CABOZANTINIB S-MALATEPrescription
CABOZANTINIB S-MALATE EQ 20MG BASE · TABLET · ORAL
CABOZANTINIB S-MALATEPrescription
CABOZANTINIB S-MALATE EQ 40MG BASE · TABLET · ORAL
Approval history
2026-10-16UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →